Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study

被引：2
|
作者：
Wang Feng [1 ]
Wang Junsheng [2 ]
Wu Tao [2 ]
Hong Yonggui [2 ]
Meng Xiangrui [1 ]
Ren Zhonghai [3 ]
Guo Yanzhen [4 ]
Yang Xiuli [5 ]
Shi Pei [5 ]
Yang Jiamei [6 ]
Fan Qingxia [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] AnYang Tumor Hosp, Anyang, Peoples R China
[3] Nanyang Cent Hosp, Nanyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 2, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [2] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Xia, Jin
    Meng, Xiangrui
    Ji, Yinghua
    Yang, Xiuli
    Hong, Yong-Gui
    Wang, Junsheng
    Cui, Donghai
    Luo, Zhiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Qi Yu
    Meng Xiangrui
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
    Wang, Feng
    Qi, Yu
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [8] Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
    Wang, Jianping
    Zhang, Jian
    Gao, Jie
    Zhao, Mengmeng
    Ma, Zhenkai
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 573 - 581
  • [9] Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial
    Wei, Zhigong
    Zhu, Yuchun
    Cai, Lei
    Peng, Xingchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
12345